Business
Qilian International Holding Group Limited Announces Inclusion of Gan Di Xin® and Qilian Shan® Oxytetracycline into List for Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals of Gansu Province
JIUQUAN, China, Nov. 23, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and
About this update from Bgm Group Ltd.
[{"type":"text","content":"JIUQUAN, China, Nov. 23, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the \"Company\"), a China-based pharmaceutical and chemical products manufacturer, today announced that Gan Di Xin® and Qilian Shan® Oxytetracycline, products of the Company's subsidiary, Gansu Qilianshan Pharmaceutical Co., Ltd. (\"Gansu QLS\"), have been included in the List for Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals of Gansu Province (the \"List\"). The List selects key medicines and medical devices with a goal of facilitating the development and promotion of leading pharmaceutical brands in Gansu Province.\nThe List was issued by the Department of Industry and Information Technology of Gansu Province (the \"Department\") on October 13, 2021 with the release of the \"Notice of the General Office of the People's Government of Gansu Province on Policies and Measures to Support the Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals of Gansu Province\". The Department has included a total of 55 medicines and medical devices from 27 enterprises, including Gan Di Xin® and Qilian Shan® Oxytetracycline from the Company.\nThe List is a major strategic decision of the Gansu provincial government (the \"Government\") as an effort to support the growth of local leading pharmaceutical companies. The Government expects to promote the development of local pharmaceutical industry, strengthen brand awareness for local companies and position Gansu province as a leading region for pharmaceutical industry through cultivating large pharmaceutical enterprises, enhancing the competitiveness of local pharmaceutical companies, and supporting pharmaceutical companies in Gansu province. The Government will include all the products on the List into Gansu Province Reimbursement Drug List and support the inclusion of all the products on the List in the National Essential Medicines List and National Reimbursement Drug List in China.\nThe Qilian Shan® and Gan Di Xin® trademarks owned by Gansu QLS are well-known domestic brands and have been favored by the market for a long time. As a global producer, manufacturer, and supplier of oxytetracycline, the Company's oxytetracycline meets the United States Pharmacopeia (the \"USP\") quality standards and their technical indicators ...